Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Characterization of biomarkers to immune checkpoint blockade therapy across solid tumors.
Authors
Meaghan Russell
KEW, Inc., Cambridge, MA
Meaghan Russell, Xiu Huang, Dana Vuzman, Maria Lvova, Angeliki Pantazi, Stephen Lyle, Julie Y Tse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Biomarkers and Inflammatory Signatures
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 26)
DOI
10.1200/JCO.2018.36.5_suppl.26
Abstract #
26
Poster Bd #
C3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).
First Author: Wafik S. El-Deiry
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2014 ASCO Annual Meeting
PD-L1 expression and genotype in non-small cell lung cancer (NSCLC).
First Author: Sascha Ansen
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox